Palmieri C, Linden H, Birrell SN, Wheelwright S, et al. Activity and safety of enobosarm, a novel, oral, selective androgen receptor modulator, in androgen receptor-positive, oestrogen receptor-positive, and HER2-negative advanced breast cancer (Study G200802): a randomised, open-label, multicentre, multin Lancet Oncol 2024 Feb 8:S1470-2045(24)00004.
PMID: 38342115